2015 American Transplant Congress
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 48
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To follow up on renal function (GFR) at month (Mo) 48 after kidney transplantation (Tx) in patients (pts) on immunosuppressive regimen with different calcineurin…2015 American Transplant Congress
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT
Background: At 3yrs, improvement in renal function was seen in kidney transplant recipients treated with belatacept (bela) vs cyclosporine (CsA) in BENEFIT. Here we report…2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…2015 American Transplant Congress
Impact of Proton Pomp Inhibitors on Hypomagnesemia and Arterial Stiffness in Renal Transplant Recipients
Purpose: Hypomagnesemia predicts cardiovascular morbidity and mortality in the general population and accelerated loss of kidney function in renal transplant recipients (RTRs). Proton pomp inhibitors…2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
1Barnes-Jewish Hospital, St. Louis, MO; 2Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…2015 American Transplant Congress
A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan
The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…2015 American Transplant Congress
Improved Renal Function Post-Liver Transplant With Earlier Everolimus Conversion
Calcineurin inhibitors (CNI) play an important role in preventing acute rejection (AR) post-liver transplant. Its long-term use is limited by development of nephrotoxicity. Optimal timing…2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
1ZEUS Study Group, Germany; 2ZEUS Study Group, Switzerland; 3Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…2015 American Transplant Congress
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy
1University of Maryland School of Medicine, Baltimore; 2Johns Hopkins University, Baltimore.
Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate…
American Transplant Congress abstracts